ACTA ENDOCRINOLOGICA (BUC)

This review provides a comprehensive analysis of drugs approved by the U.S. Food and Drug Administration (USFDA) for managing diabetes mellitus (DM) from 2013 to 2022, including emerging treatments from phase 3 clinical trials during this period. By combining data from approved drugs and promising contenders, we provide insights into the changing landscape of DM care. A thorough examination of phase 3 clinical studies that focused on treatments for diabetes mellitus (DM), utilizing data collected from ClinicalTrials. gov. Furthermore, we made sure to only include trials with documented outcomes in our analysis. Our study uncovers a wide range of innovative compounds in phase 3 trials, aiming at DM through diverse action mechanisms.